WEBNEWS RELEASE Registered office VIA M. CIVITALI, 1 20148 MILAN, ITALY ... BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI 00748210150 TAX CODE/VAT NO. 00748210150 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A. RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ... Enjaymo® generated approximately € 100 million in revenue ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB3 days ago · Enjaymo reeled in sales of around 100 million euros ($110 million) over 12 months ending in August, Recordati said in its release. The drug is expected to generate revenues in the vicinity of 150 ...
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For …
WEB3 days ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB4 days ago · Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB4 days ago · Recordati is paying $825 million up front for global rights to Enjaymo, a drug that is approved in the U.S., Japan, and Europe. If the drug achieves sales milestones, the company could pay out up ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB3 days ago · Global News Select Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million ... Enjaymo's revenue amounted to around 100 million euros ($110.3 million) for the 12 months to August and ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEB3 days ago · SNY. (Reuters) - Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEB3 days ago · Recordati said the agreement it signed was for the rights to Enjaymo, a biologic which is the only targeted product for the treatment of CAD approved by the U.S. Food and Drug Administration (FDA).
Sanofi Offloads Rare Autoimmune Drug to Recordati in
WEB3 days ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB3 days ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
- Some results have been removed